Rationale and prospects for the use of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer;Rationnel et perspectives d'utilisation des inhibiteurs de cyclooxygénase-2 (COX-2) dans les cancers colorectaux

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 11, 2001, Pages 967-978

  Buecher, Bruno ^a   Heymann, Marie Françoise ^a   Blottière, Hervé M ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN SYNTHASE; SULINDAC SULFIDE;

CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CANCER; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE STRUCTURE; HUMAN; REVIEW;

EID: 0035208802     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Prostacyclin synthesis in ovine pulmonary artery is developmentally regulated by changes in cyclooxygenase-1 gene expression
2. Recent advances in inducible cyclooxygenase (COX-2) inhibition
3. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme
4. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2
5. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells
6. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids
7. Prostaglandin endoperoxide synthase: Why two isoforms ?
8. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells
9. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
10. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
11. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
12. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
13. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
14. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal antiinflammatory drug NS-398
15. Par-4, a proapoptotic gene, is up-regulated by NSAIDs in human colon carcinoma cells
16. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
17. Prevention by aspirin and its combination with alpha-difluoromethylomithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon
18. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
19. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
20. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
21. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX2)
22. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
23. Inhibition of human colon cancer cell growth by selective inhibitor of cyclooxygenase 2
24. La consommation d'aspirine ou d'anti-inflammatoires non stérïdiens diminue-t-elle le risque de cancer colique ? Conférence de consensus - Texte des experts
25. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
26. Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents
27. Aspirin use and reduced risk of fatal colon cancer
28. Aspirin use and risk of fatal cancer
29. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
30. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
31. Aspirin and the risk of colorectal cancer in women
32. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: A population-based study
33. Colorectal cancer prevention by non-steroidal antiinflammatory drugs: Effects of dosage and timing
34. Effect of antiinflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
35. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease
36. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs
37. Effect of aspirin and non-steroidal anti -inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
38. Aspirin use, cancer, and polyps of the large bowel
39. Reduced risk of large-bowel adenomas among aspirin users
40. Aspirin and other nonsteroidal antiinflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
41. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia
42. Aspirin and nonsteroidal antiinflammatory agents and risk for colorectal adenomas
43. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas
44. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: A pooled analysis of published studies and a new-population based study
45. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs
46. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
47. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 treatment in human colon cancer cells
48. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
49. Sulindac inhibits activation of the NF-κ B pathway
50. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
51. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: An in vitro study
52. Sulindac, and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane
53. Identification of c-MYC as a target of the APC pathway
54. PPARδ is an APC-regulated target of nonsteroidal antiinflammatory drugs
55. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer
56. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
57. Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
58. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP
59. Host cyclooxygenase-2 modulates carcinoma growth
60. Prostaglandin H synthase and xenobiotic oxidation
61. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
62. Cancer du côlon: Épidémiologie descriptive et groupes à risque élevé. Conférence de consensus. Prévention, dépistage et prise en charge des cancers du côlon
63. Sulindac for polyposis of the colon
64. Sulindac treatment for familial polyposis coli
65. Efficacité du sulindac dans le traitement de la polypose rectocolique
66. Sulindac for polyposis of the colon
67. Micropolypes rectaux après colectomie totale pour polypose familiale: Efficacité du sulindac
68. Effects of long-term sulindac therapy on colonic polyposis
69. NSAID effect on sporadic colon polyps
70. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment
71. Sulindac in familial adenomatous polyposis coli: Preliminary findings of a prospective study
72. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: Evaluation of predictive factors
73. Long-term treatment with sulindac in familial adenomatous polyposis: Is there an actual efficacy in prevention of rectal cancer?
74. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy
75. Rectal cancer in FAP patient after sulindac
76. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment
77. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
78. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
79. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous
80. The effect of cclccoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
81. Sulindac for periampullary polyps in FAP patients
82. The effect of celecoxib on duodenal polyposis in familial adenomatous polyposis (FAP)
83. Colorectal cancer risk in HNPCC families: Development during lifetime and in successive generations
84. Cancer risk in families with hereditary non polyposis cancer diagnosed by mutation analysis
85. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers
86. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection
87. Effects of sulindac on sporadic colorectal adenomatous polyps
88. Rectal cancer after sulindac therapy for sporadic adenomatous colonic polyps
89. NSAID effect on sporadic colon polyps
90. Effect of sulindac on sporadic colonic polyps
91. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
92. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians'Health Study
93. Conclusions et recommandations du Jury. Texte du consensus. Prévention, dépistage et prise en charge des cancers du côlon